A biomarker combination, primer-probe combination and application thereof for detecting oral cancer and esophageal cancer

By using the combination of methylated primer probes of NID2, PAX1, ZNF154 and ZNF582 genes, combined with PCR technology, the existing oral cancer esophageal cancer detection methods have solved the problems of low sensitivity and specificity and high invasiveness, and achieved high sensitivity , Non-invasive or minimally invasive detection with high specificity reduces the artificial interference of the test results.

CN118685522BActive Publication Date: 2024-11-19湖南宏雅基因技术有限公司
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202411170062.7
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2024-08-26
Publication Date
2024-11-19
Estimated Expiration
2044-08-26

AI Technical Summary

Technical Problem

The existing oral cancer esophageal cancer detection methods have problems such as invasiveness, false negative risk, low sensitivity and high cost. In particular, imaging examinations are less sensitive to early tumors, and the cytology results are greatly affected by the quality of the sample.

Method used

The NID2, PAX1, ZNF154 and ZNF582 genes were used as biomarkers to design the corresponding methylation primer probe combination, and the gene methylation sequence was amplified by PCR reaction program, and combined with GAPDH as an internal reference gene, providing it for the oral cavity. The kit for carcinoesophageal cancer detection is a positive result of polygenic methylation combination.

Benefits of technology

It improves the sensitivity and specificity of the detection, reduces the requirements for cell quantity and quality, makes the detection results more objective, has the characteristics of non-invasive or minimally invasive sampling, reduces artificial interference, and improves the reliability of the detection.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118685522B_ABST
    Figure CN118685522B_ABST
Patent Text Reader

Abstract

The present invention provides a biomarker combination, a primer probe composition and an application thereof for detecting oral cancer and esophageal cancer, and relates to the technical field of detecting oral cancer and esophageal cancer, wherein the biomarker combination comprises at least two of the NID2 gene, the PAX1 gene, the ZNF154 gene and the ZNF582 gene. The present invention screens out a new marker methylation as a biomarker for detecting oral cancer and esophageal cancer, and judges the screened new marker methylation combination, so that the result is objective and not interfered by human factors, and has the characteristics of higher sensitivity and specificity.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the technical field of oral cancer and esophageal cancer detection, and in particular to a biomarker combination, a primer-probe composition and an application thereof for oral cancer and esophageal cancer detection. Background Art

[0002] Oral cancer is a malignant tumor that occurs in the oral mucosa, including lip cancer, tongue cancer, gum cancer, cheek cancer, and mouth floor cancer. The existing methods for detecting oral cancer include:

[0003] ① Endoscopic examination is currently the most direct and reliable method for diagnosing oral esophageal cancer. Through esophagoscopy or laryngoscopy, doctors can directly observe the condition of the esophageal mucosa and perform biopsies to confirm whether cancer exists. However, endoscopic examination is an invasive method, which will cause discomfort to patients and requires professional endoscopists to perform the operation. There may be certain false negative results. Endoscopic examination is an invasive examination method, and hidden lesions or hidden sites cannot be clearly identified, thus there is a risk of missing the rash.

[0004] ② Oral exfoliated cell examination includes cotton swab sampling of suspected lesions and mouthwash sampling of unclear lesion sites. Exfoliated cells of the esophagus can be obtained by pulling the net method. The patient is in an empty stomach state, and the esophagus is anesthetized with local anesthetics. A thin and soft mesh cable is used, and a movable collector is connected to the end of the mesh cable. The collector is attached with a sticky substance that can collect exfoliated cells. The doctor slowly inserts the mesh cable into the esophagus through the mouth until it reaches the predetermined collection area. The mesh cable is unfolded in the esophagus, covering a certain area. As the mesh cable moves, the sticky substance will collect the exfoliated cells on the surface of the esophagus. After the collection is completed, the mesh cable is taken out together with the collected cells and placed in a specific cell preservation fluid for cytological analysis. Cytological examination is relatively non-invasive and has high patient acceptance. However, cytological evaluation requires professional physicians, and the results are greatly affected by the quality of the sample, and the clinical sensitivity is not high; and the use of cytological examination has high requirements for the quality of cells, and its test results are easily interfered by the quality of cells, resulting in the risk of low sensitivity.

[0005] ③ Imaging examinations such as CT and MRI are non-invasive and do not cause damage to the patient's body. They can observe the condition of the oral esophageal surrounding tissues and lymph nodes. However, imaging has a low sensitivity for early tumors and requires large equipment and professional physicians, which is relatively expensive.

[0006] Based on this, in many current cancer detection applications, silencing of tumor suppressor genes through promoter methylation is an early event in carcinogenesis, and may even be more frequent than gene structure inactivation caused by mutation and deletion, and may be more sensitive to cancer. Summary of the invention

[0007] The present invention provides a biomarker combination for detecting oral cancer and esophageal cancer, wherein the biomarker combination consists of NID2 gene, PAX1 gene, ZNF154 gene and ZNF582.

[0008] Optionally, the target region of the NID2 gene is selected from chr14:52535446-52535932;

[0009] The target region of the PAX1 gene is selected from chr20:21686665-21687095;

[0010] The target region of the ZNF154 gene is selected from chr19:58219905-58220755;

[0011] The target region of the ZNF582 gene is selected from chr19:56904340-56905175.

[0012] Optionally, the primer-probe composition includes the above-mentioned biomarker combination as a primer-probe sequence corresponding to the methylation marker, and the primer-probe sequence is specifically represented as follows:

[0013] The forward primer sequence of NID2 gene: GGTTGAGTTTTCGTCGTCGTT, the rear primer sequence of NID2 gene: CTACTACTACTACCGTTACTAATATTACGA, the probe sequence of NID2 gene: CGCTACACCCAAACGAACTCTTCCCAC;

[0014] The forward primer sequence of PAX1 gene: GATAGTTCGGAGTTTAAGGGTAAATCG, the rear primer sequence of PAX1 gene: AACTACAATACGCCGCGCTC, the probe sequence of PAX1 gene: CGACTCCTCTACGCCCTTACCCACTC;

[0015] The forward primer sequence of ZNF154 gene: GTCGTATTTATTTGAGTTGGCGTTT, the rear primer sequence of ZNF154 gene: AAACCGCTATCCCCGAATCC, the probe sequence of ZNF154 gene: TACCAATATCGCCCGTCGCTCCCGA;

[0016] The forward primer sequence of ZNF582 gene: CGCGTTTTCGGTAGTTTAGGG, the rear primer sequence of ZNF582 gene: TAACGCAACATCGATATACTTTATACG, the probe sequence of ZNF582 gene: ACGCCATCTTCCGACTACGCACGA.

[0017] Optionally, a set of primer probe sequences corresponding to a reference marker GAPDH gene is also included, which are specifically represented as follows:

[0018] The forward primer sequence of GAPDH gene: GAGGTTAAATATAGTTGTTGA,

[0019] The forward primer sequence of GAPDH gene: CCCAAAACTTTAATTTACCA,

[0020] The probe sequence of GAPDH gene: ACCTATCCTTCCTAACTCT.

[0021] The present invention also provides a group of uses of the primer-probe combination as described above in preparing a kit for detecting oral cancer and esophageal cancer.

[0022] Optionally, when the NID2 gene, PAX1 gene, ZNF154 gene and ZNF582 gene are used in combination as a detection primer-probe combination, the interpretation criteria are:

[0023] GENE1m+GENE2m+GENE3m+GENE4>3, that is, NID2 gene, PAX1 gene, ZNF154 gene and ZNF582 gene are all positive and are judged as positive;

[0024] GENE1m+GENE2m+GENE3m+GENE4>2 is positive, that is, any three genes among NID2 gene, PAX1 gene, ZNF154 gene and ZNF582 gene are positive;

[0025] GENE1m+GENE2m+GENE3m+GENE4>1 is positive, that is, any two genes among NID2 gene, PAX1 gene, ZNF154 gene and ZNF582 gene are positive;

[0026] GENE1m+GENE2m+GENE3m+GENE4>0 is positive, that is, any one of the NID2 gene, PAX1 gene, ZNF154 gene and ZNF582 gene is positive;

[0027] Among them, GENE1m represents the first gene methylation detection result of the four gene methylation combination, GENE2m represents the second gene methylation detection result of the four gene methylation combination, GENE3m represents the third gene methylation detection result of the four gene methylation combination, and GENE4m represents the fourth gene methylation detection result of the four gene methylation combination.

[0028] Compared with the prior art, the present invention has the following beneficial effects:

[0029] (1) The present invention screens out new marker methylation as a biomarker for the detection of oral cancer and esophageal cancer, and judges the screened new marker methylation combination, so that the result is objective and not affected by human factors, and has the characteristics of higher sensitivity and specificity.

[0030] (2) The present invention has the characteristics of non-invasive or minimally invasive sampling by taking mouthwash or cotton swab specimens from patients undergoing oral cancer examinations and taking exfoliated cell specimens from patients undergoing esophageal cancer examinations by using a net pulling method.

[0031] (3) The present invention uses a PCR reaction procedure to amplify the gene methylation sequence, which has lower requirements on the number or quality of cells compared to the existing method of exfoliative cytology.

[0032] In addition to the above-described purposes, features and advantages, the present invention has other purposes, features and advantages. The present invention will be further described in detail with reference to the accompanying drawings. BRIEF DESCRIPTION OF THE DRAWINGS

[0033] The drawings constituting a part of this application are used to provide a further understanding of the present invention. The exemplary embodiments of the present invention and their descriptions are used to explain the present invention and do not constitute an improper limitation of the present invention. In the drawings:

[0034] Figure 1 is a ROC diagram of NID2 methylation for diagnosing oral cancer in the experimental example of the present invention;

[0035] Figure 2 is a ROC diagram of PAX1 methylation in diagnosing oral cancer in the experimental example of the present invention;

[0036] Figure 3 is a ROC diagram of ZNF154 methylation for diagnosing oral cancer in the experimental example of the present invention;

[0037] Figure 4 is a ROC diagram of ZNF582 methylation for diagnosing oral cancer in the experimental example of the present invention;

[0038] Figure 5 is the ROC diagram of NID2 methylation in diagnosing esophageal cancer in the experimental example of the present invention;

[0039] Figure 6 is the ROC diagram of PAX1 methylation in diagnosing esophageal cancer in the experimental example of the present invention;

[0040] Figure 7 is the ROC diagram of ZNF154 methylation in diagnosing esophageal cancer in the experimental example of the present invention;

[0041] Figure 8is the ROC diagram of ZNF582 methylation in diagnosing esophageal cancer in the experimental example of the present invention;

[0042] Fig. 9 It is the ROC diagram of the weighted joint diagnosis of esophageal cancer by four-gene methylation in the experimental example of the present invention. DETAILED DESCRIPTION

[0043] The following are specific embodiments of the present invention and the accompanying drawings to further describe the technical solution of the present invention, but the present invention is not limited to these embodiments.

[0044] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as those commonly understood by those skilled in the art of the present invention. The terms used in the present invention specification herein are only for the purpose of describing specific embodiments and are not intended to limit the present invention. Embodiment 1:

[0045] 1. Screening of gene methylation markers

[0046] The genes and target regions were selected: NID2 (chr14:52535446-52535932), PAX1 (chr20:21686665-21687095), ZNF154 (chr19:58219905-58220755), and ZNF582 (chr19:56904340-56905175) as markers for oral cancer and esophageal cancer.

[0047] (II) Design primers and probes for gene methylation detection and combine them into a kit

[0048] After determining the methylated genes of oral cancer and esophageal cancer, the gene GAPDH (chr12:6644961-6645168) was used as the internal reference gene (IC), and PCR primers and probes for methylation detection were designed.

[0049] Specifically, the methylation region sequence of the gene NID2 was selected from the DNA strand in UCSC Genome Browser on Human (GRCh37 / hg19), hg19_dna range=chr14:52535446-52535932 5'pad=0 3'pad=0 strand=+:

[0050] GAAGCTGCGGGAAAAGTGCCAGGAGGGGGCTGAACTTACGTAGAGGTTGCTGAATCGGGCTTCGTAGAAGTGCAGGGGATTCGCCAGCTTCACCACGGCTGAGCTTTCGTCGTCGCCTTCCTGCAGGAGCTGGTCCCCCCACGACTCCCCGTGTGGGAAGAGCTCGTCTGGGTGCAGCGCCGCGGCCCGCAACATTAGCAACGGCAGCAGCAGTAGCACTGGTAACGACGACAGCACCGGCCG CCCGGCCACCCGGTCCCCTCCATGCTCGCTCGGCCGTGCGCTTACCCGCTGCACAACGCGTCCCGCCCCGCCTCCAGCCCACTCTCCGCGCCGCGCCAGCCTCGAACCTGGATCTCCGGGGCGCCTGGGCGGGGCGGGACTCCAGGCCCACCCAGCAAGCTAATTGGCTGAGGCCCTCGGCTGGGGACCAATCACCGGCTCTGAGAAAGTTCGGCAGTGGCCACCACATCTGGTTCTCGTT

[0051] All C in CG in this DNA sequence is methylated and bisulfite converted (unmethylated C is converted to T, and methylated C remains unchanged) to obtain the converted DNA chain (B-DNA):

[0052] GAAGTTGCGGGAAAAGTGTTAGGAGGGGGTTGAATTTACGTAGAGGTTGTTGAATCGGGTTTCGTAGAAGTGTAGGGGATTCGTTAGTTTTATTACGGTTGAGTTTTCGTCGTCGTTTTTT TGTAGGAGTTGGTTTTTTTACGATTTTTCGTGTGGGAAGAGTTCGTTTGGGTGTAGCGTCGCGGTTCGTAATATTAGTAACGGTAGTAGTAGTAGTATTGGTAACGACGATAGTATCGGTCG TTCGGTTATTCGGTTTTTTTATGTTCGTTCGGTCGTGCGTTTATTCGTTGTATAACGCGTTTCGTTTCGGTTTTTAGTTTATTTTTCGCGTCGCGTTAGTTTCGAATTTGGATTTTCGCGGGCGTTTGGGCGGGGCGGGATTTTAGGTTTATTTAGTAAGTTAATTGGTTGAGGTTTTTCGGTTGGGGATTAATTATCGGTTTTGAGAAAGTTCGGTAGTGGTTATTATTTGGTTTTCGTT

[0053] Based on the converted DNA chain sequence, the methylation primer probe sequence position of NID2 (chr14:52535446-52535932) was obtained.

[0054] Specifically, the methylation region sequence of the gene PAX1 was selected from the DNA strand in UCSC Genome Browser on Human (GRCh37 / hg19), hg19_dna range=chr20:21686665-21687095 5'pad=0 3'pad=0 strand=-:

[0055] CACCTCGCCATACGTCTGCTCTGCGGATGCGCCAGACAAGAGTGAGCCGGAGGGGGAGAAAACACCCGGCGGGTTAGCCAAGGGTCCCCACGCGGAGCGAGGGACTGCACCCAGGCGCACTTCCAAAGGTGACCTGTGGGTCCCCAGACAGCTCGGAGTCCAAGGGCAAACCGCCTGGGTCTGGCTTGGAGTGGGCAAGGGCGCAGAGGAGCCGCGGAGTGGAGCGCGGCGCATTGTAGCCCTCCGTGCCCTTTCGCGACTTTTAGCGCGTCTACTTGGAACACTCCCTTCCCAGACTTGCTCAACTGCCCCCTGAAGGCTGGGGATCAGAGGAGAATGCAGCTTCTCCAGGACCCAGGACTGGGTCGCCCAGGGAAAGCGGACGAGAGGGAAGGGAGGCAGGCGGACCCGACCCACCTCATCAGCCCTCC

[0056] All the C in CG of this DNA sequence is methylated. After bisulfite conversion (unmethylated C is converted to T, and methylated C remains unchanged), the converted DNA strand (B-DNA) is obtained:

[0057] TATTTCGTTATACGTTTGTTTTGCGGATGCGTTAGATAAGAGTGAGTCGGAGGGGGAGAAAATATTCGGCGGGTTAGTTAAGGGTTTTTACGCGGAGCGAGGGATTGTATTTAGGCGTATTTTTAAAGGTGATTTGTGGGTTTTTAGATAGTTCGGAGTTTAAGGGTAAATCGTTTGGGTTTGGTTTGGAGTGGGTAAGGGCGTAGAGGAGTCGCGGAGTGGAGCGCGGCGTATTGTAGTTTTTCGTGTTTTTTCGCGATTTTTAGCGCGTTTATTTGGAATATTTTTTTTTTAGATTTGTTTAATTGTTTTTTGAAGGTTGGGGATTAGAGGAGAATGTAGTTTTTTTAGGATTTAGGATTGGGTCGTTTAGGGAAAGCGGACGAGAGGGAAGGGAGGTAGGCGGATTCGATTTATTTTATTAGTTTTTC

[0058] Based on the converted DNA chain sequence, the methylation primer probe sequence position of PAX1 (chr20:21686665-21687095) was obtained.

[0059] Specifically, the methylation region sequence of gene ZNF154 was selected from UCSC Genome Browser on Human (GRCh37 / hg19), hg19_dna range=chr19:58219905-58220755 5'pad=0 3'pad=0 strand=+ in the DNA strand:

[0060] CACTCCAGCCTGGGCGATAAGAGCGAAACTCCGTCTCAAAGAAAAAAAAACTAACATAAATGGCGTCCCTCCTTTGTTCAGAACTCTCCGTGGCTTCTAGCATCCTCACAATGACAGTACAACCCTAGGAGTAACTCCGCCTCATATTCTTCGTTCCCTGCAGAAAACAGCTTTCCGAATTCTCCTGGCTCAGTCGCGCCTCAACCTTTGCACGCGCCGGTTCCTCCGCCTGTCACGCTCTCCCACACCTCGTCACACGCAGTGTCAAAAAAAGGGCCCCACCCACGAACGCCTCAGTGTCCCCGACCCTGGGCAGCGGGGACTCGAGCAGGCGCCCCTCACTGATGGCTTTAGAACGTGGGTGGGGGAAGGTGTGTGAGGACGGGAAGACGCCGCACTCACCTGAGTTGGCGTCCTCAGAGTGGCCGCTGCCATCAGACTCTGCGGGTAGAGCTGGGCCGGGAGCGACGGGCGACATTGGTAGGGACCCGGGGACAGCGGTCCCTATCCCAGGCCTGACGTGGGTCCCCCAGGGCGGCGTCGCCAAGGCTTAGACGCTTTCGTGCAGGAGGGACGACGACTCCCCTCACGCCTTCGTGGCCCCAACTCGGCGCTCTGCTATCTCTGATCCGGTGAACACACCTCAGAGAAGCTAAAATGGCCGCCACGAAGAGGCCCCCCCAAAAGTCCCGTCCTTTCTTTTTGTGACTCTCAAGGAAAGTCGGTTTTCTGAGCTCTTACTGGCTTAGTAGCGTGGCGTTCAACGCAGAGCATTCTAGGTAATGTAGTTTTCATAGATCCCGAGGTGGGTGCCGGGGACCCTTTGCACCAACCTCTTGGAGTAAAAGCGA

[0061] All the Cs in CG of this DNA sequence are methylated. After bisulfite conversion (unmethylated Cs are converted to Ts, and methylated Cs remain unchanged), the converted DNA strand (B-DNA) is obtained:

[0062] TATTTTAGTTTGGGCGATAAGAGCGAAATTTCGTTTTAAAGAAAAAAAAATTAATATAAATGGCGTTTTTTTTTTGTTTAGAATTTTTCGTGGTTTTTAGTATTTTTATAATGATAGTATAATTTTAGGAGTAATTTCGTTTTATATTTTTCGTTTTTTGTAGAAAATAGTTTTTCGAATTTTTTTGGTTTAGTCGCGTTTTAATTTTTGTACGCGTCGGTTTTTTCGTTTGTTACGTTTTTTTATATTTCGTTATACGTAGTGTTAAAAAAAGGGTTTTATTTACGAACGTTTTAGTGTTTTCGATTTTGGGTAGCGGGGATTCGAGTAGGCGTTTTTTATTGATGGTTTTAGAACGTGGGTGGGGGAAGGTGTGTGAGGACGGGAAGACGTCGTATTTATTTGAGTTGGCGTTTTTAGAGTGGTCGTTGTTATTAGATTTTGCGGGTAGAGTTGGGTCGGGAGCGACGGGCGATATTGGTAGGGATTCGGGGATAGCGGTTTTTATTTTAGGTTTGACGTGGGTTTTTTAGGGCGGCGTCGTTAAGGTTTAGACGTTTTCGTGTAGGAGGGACGACGATTTTTTTTACGTTTTCGTGGTTTTAATTCGGCGTTTTGTTATTTTTGATTCGGTGAATATATTTTAGAGAAGTTAAAATGGTCGTTACGAAGAGGTTTTTTTAAAAGTTTCGTTTTTTTTTTTTGTGATTTTTAAGGAAAGTCGGTTTTTTGAGTTTTTATTGGTTTAGTAGCGTGGCGTTTAACGTAGAGTATTTTAGGTAATGTAGTTTTTATAGATTTCGAGGTGGGTGTCGGGGATTTTTTGTATTAATTTTTTGGAGTAAAAGCGA

[0063] Based on the converted DNA strand sequence, the methylation primer-probe sequence positions of ZNF154 (chr19:58219905-58220755) are obtained.

[0064] Specifically, the methylation region sequence of gene ZNF582 is selected from the DNA strand in UCSC Genome Browser on Human (GRCh37 / hg19), hg19_dna range=chr19:56904340-56905175 5'pad=0 3'pad=0 strand=+:

[0065] ATTTACAAAGGATGGCCTGTGATCCACTCAAGTGTTTCCCCATTGCTGGACATAGAATTTGAACATATAAAATGTTCCCAAGTATAAGTTTTTCTAAACTAGCGGTTCTAAGTCTTCTGGGGTCTTGTAACTCTCTGAGAACCTCATGAAACAAGATTTCCTCTCAGATTAAAAAAAAAAAAAGGCACGCATAACAGTGAATGCAAAACATCCGCAATTTCAGGGGGTCGGAGACCCCTGCGCACCCACCTAAGGGGTCCATGCACCTGGGCTATGAGGCTGGAAGCAGAAAGGGGGCGCCAGAAAGCGCACGCCGCGAGGGCCGGCGGGAAATGTAGTCTCACGCCGGTAAAGCCACAGAGCGACGATGAGGCGAGACGTCTGCGTTCTTCTCAGGCCTGAGACCCAACCGGCCCGGGCACCAGCTCCTGCTGGACCCCAGAGCGCCTGGAAAGCTCCGGAACCTCTCACCTGCCGCCTCCTCGGGTCCAAGTGCCACCGCGGCCGCGCCCCCGGCAGCCCAGGGCGCGCTTCCACCACGGTACCGGTGGATTCGCCGTGCGCAGCCGGAAGATGGCGCAGACGCACAAAGCACACCGATGCTGCGCCATGATAGGGCCGGCGCCGCAGTGTCTTCCGGGAAACATAGTCTTTAGGCGTAAAGGCAGCAGCCCGGCCTTGAAGCCGGATCTCGCGATGTTTCAGGGTGAGCCGGACGCAGGCGTGCCTGCGCAGTGCGCGGAGGAGTGCTGTTCGTGTGTTCGAGTCCCTGGGTTGCTTCCTGGGGTCTGTGGTGCTGGGTGTGCTATCTGCGTGTGATTCTCTAGCGAGAGATT

[0066] All the Cs in CG of this DNA sequence are methylated. After bisulfite conversion (unmethylated C is converted to T, and methylated C remains unchanged), the converted DNA strand (B-DNA) is obtained:

[0067] ATTTATAAAGGATGGTTTGTGATTTATTTAAGTGTTTTTTTATTGTTGGATATAGAATTTGAATATATAAAATGTTTTTAAGTATAAGTTTTTTTAAATTAGCGGTTTTAAGTTTTTTGGGGTTTTGTAATTTTTTGAGAATTTTATGAAATAAGATTTTTTTTTAGATTAAAAAAAAAAAAAGGTACGTATAATAGTGAATGTAAAATATTCGTAATTTTAGGGGGTCGGAGATTTTTGCGTATTTATTTAAGGGGTTTATGTATTTGGGTTATGAGGTTGGAAGTAGAAAGGGGGCGTTAGAAAGCGTACGTCGCGAGGGTCGGCGGGAAATGTAGTTTTACGTCGGTAAAGTTATAGAGCGACGATGAGGCGAGACGTTTGCGTTTTTTTTAGGTTTGAGATTTAATCGGTTCGGGTATTAGTTTTTGTTGGATTTTAGAGCGTTTGGAAAGTTTCGGAATTTTTTATTTGTCGTTTTTTCGGGTTTAAGTGTTATCGCGGTCGCGTTTTCGGTAGTTTAGGGCGCGTTTTTATTACGGTATCGGTGGATTCGTCGTGCGTAGTCGGAAGATGGCGTAGACGTATAAAGTATATCGATGTTGCGTTATGATAGGGTCGGCGTCGTAGTGTTTTTCGGGAAATATAGTTTTTAGGCGTAAAGGTAGTAGTTCGGTTTTGAAGTCGGATTTCGCGATGTTTTAGGGTGAGTCGGACGTAGGCGTGTTTGCGTAGTGCGCGGAGGAGTGTTGTTCGTGTGTTCGAGTTTTTGGGTTGTTTTTTGGGGTTTGTGGTGTTGGGTGTGTTATTTGCGTGTGATTTTTTAGCGAGAGATT

[0068] Based on the converted DNA chain sequence, the methylation primer probe sequence position of ZNF582 (chr19:56904340-56905175) was obtained. Embodiment 2:

[0069] 1. Construct a PCR system for gene methylation detection;

[0070] 1. Nucleic acid DNA pretreatment, the specific process is as follows:

[0071] The extracted DNA is treated with Hongya Gene's methylation pretreatment kit to convert cytosine in the DNA into uracil. The treated DNA is purified by nucleic acid purification kits and other methods to remove excess salts and bisulfites. The treated DNA is stored at -20℃ or 4℃. It is recommended to store it at 4℃ for one week and at -20℃ for one month before completing the gene methylation test.

[0072] 2. Construct a PCR reaction system. The specific process is as follows:

[0073] Before synthesizing the primer probes for the four target genes and one internal reference gene, different fluorescent groups are attached to the 5' end of the probe, and the corresponding appropriate quenching group is attached to the 3' end of the probe, so that the four genes can be amplified in different reaction systems or in the same reaction system. The reaction system can be 25 μl or 50 μl. The 25 μl system is 10×PCR reaction MIX plus 2.5 μl, NID2 front primer plus 0.2-0.5 μl, NID2 rear primer plus 0.2-0.5 μl, NID2 probe plus 0.2-0.5 μl, PAX1 front primer plus 0.2-0.5 μl, PAX1 rear primer plus 0.2-0.5, PAX1 probe plus 0.2-0.5 μl, ZNF154 front primer plus 0.2-0.5 μl, ZNF154 rear primer plus 0.2 -0.5 μl, ZNF154 probe plus 0.2-0.5 μl, ZNF582 front primer plus 0.2-0.5 μl, ZNF582 rear primer plus 0.2-0.5 μl, ZNF582 probe plus 0.2-0.5 μl, GAPDH front primer plus 0.2-0.5 μl, GAPDH rear primer plus 0.2-0.5 μl, GAPDH probe 0.2-0.5 μl, B-DNA plus 2 μl, double distilled water added to the total volume of 25 μl. Among them, PCR reaction MIX is a PCR buffer containing 4 kinds of dNTPs, thermostable DNA polymerase, magnesium ions, etc., B-DNA is a nucleic acid DNA converted by bisulfite, or an externally synthesized target gene or internal reference gene methylated nucleic acid.

[0074] 3. PCR reaction program, the specific settings are as follows:

[0075] The prepared PCR reaction system is placed on a fluorescent quantitative PCR instrument, and the matching PCR reaction program is set to amplify the gene methylation sequence. The PCR reaction program is:

[0076] ① Pre-denaturation at 95℃ for 5-10 minutes to denature DNA and activate DNA polymerase;

[0077] ② Denature at 90℃-95℃ for 15-30 seconds to separate the double-stranded DNA into single-stranded DNA;

[0078] ③, anneal at 50℃-65℃ for 15-30 seconds to allow the primer to bind to the target DNA sequence;

[0079] ④, extend at 60℃-75℃ for 15-60 seconds, DNA polymerase synthesizes new DNA chain along the template DNA chain, set ②, ③, ④ to cycle 50 times, and record fluorescence;

[0080] ⑤. Terminate the PCR reaction and store the product at 4°C for analysis.

[0081] 2. Establishing standards for clinical interpretation of gene methylation;

[0082] 1. The criteria for judging gene methylation are as follows:

[0083] The detection results of single gene methylation levels are recorded as GENEm, NID2 gene methylation is recorded as NID2m, PAX1 gene methylation is recorded as PAX1m, and ZNF154 gene methylation is recorded as ZNF154m. The Ct value is the time when the PCR amplification curve crosses the threshold line, which is the abbreviation of Cycle threshold.

[0084] The specimens for oral cancer detection are mouthwash or cotton swab specimens, and the single gene methylation detection result is ΔCt (GENE) = Ct (GENE) - Ct (IC). The interpretation of the single gene methylation result is ΔCt (GENE) ≤ k (5-15) for positive, recorded as 1; ΔCt (GENE) > k or no peak is negative, recorded as 0. The specimens for esophageal cancer detection are esophageal exfoliated cells obtained by the net method, and the single gene methylation detection result is Ct (GENE). The single gene methylation result is interpreted as Ct (GENE) ≤ m (28-48) for positive, recorded as 1; Ct (GENE) > m or no peak is negative, recorded as 0.

[0085] 2. Interpretation of dual gene methylation combined detection is as follows:

[0086] Select any two gene methylation combinations from the NID2 gene, PAX1 gene, ZNF154 gene, and ZNF582 gene as the detection primer-probe combination, and record the detection result of the methylation level of the first gene in the any two gene methylation combinations as GENE1m, and record the detection result of the methylation level of the other gene in the any two gene methylation combinations as GENE2m, then the result of the double gene methylation combined detection is GENE1m+GENE2m;

[0087] The judgment standard is: any gene methylation is positive and is judged as positive, that is, GENE1m+GENE2m>0 is positive.

[0088] 3. The interpretation criteria for the results of the three-gene methylation combined detection are as follows:

[0089] Select any three gene methylation combinations of NID2 gene, PAX1 gene, ZNF154 gene and ZNF582 gene as the detection primer probe combination, and record the methylation level detection result of the first gene in any three gene methylation combination as GENE1m, record the methylation level detection result of the second gene in any three gene methylation combination as GENE2m, and record the methylation level detection result of the third gene in any three gene methylation combination as GENE3m. The result of the joint detection of the methylation of the three genes is GENE1m+GENE2m+GENE3m, and the results are 0, 1, 2 and 3 respectively.

[0090] The judgment criteria are:

[0091] ①GENE1m+GENE2m+GENE3m>2, that is, all three genes are positive and are judged as positive;

[0092] ②GENE1m+GENE2m+GENE3m>1, that is, any two genes are positive and are judged as positive;

[0093] ③GENE1m+GENE2m+GENE3m>0, that is, any one gene positive is judged as positive.

[0094] 4. The interpretation criteria for the results of the four-gene methylation combined detection are as follows:

[0095] The NID2 gene, PAX1 gene, ZNF154 gene and ZNF582 gene were selected together as a detection primer probe combination, and the methylation level detection result of the first gene was recorded as GENE1m, the methylation level detection result of the second gene was recorded as GENE2m, the methylation level detection result of the third gene was recorded as GENE3m, and the methylation level detection result of the fourth gene was recorded as GENE4m. The result of the combined methylation detection of the four genes was GENE1m+GENE2m+GENE3m+GENE4, and the results were 0, 1, 2, 3 and 4 respectively.

[0096] The judgment criteria are:

[0097] ①GENE1m+GENE2m+GENE3m+GENE4>3, that is, all four genes are positive and are judged as positive;

[0098] ②GENE1m+GENE2m+GENE3m+GENE4>2 is positive, that is, any three genes are positive;

[0099] ③GENE1m+GENE2m+GENE3m+GENE4>1 is positive, that is, any two genes are positive;

[0100] ④GENE1m+GENE2m+GENE3m+GENE4>0 is positive, that is, any one gene is positive and is judged as positive.

[0101] NID2m / PAX1m / ZNF154m / ZNF582m were weightedly combined, and each gene methylation positive was assigned different scores according to the weight, and negative was assigned 0 points. Different critical values ​​were taken in combination with the clinical requirements for sensitivity or specificity. Embodiment 3:

[0102] The present invention also provides a method for detecting oral cancer and / or esophageal cancer using the above-mentioned biomarker combination, the specific process of which is as follows:

[0103] 1. Primer probe synthesis;

[0104] According to the primer and probe sequences of genes NID2, PAX1, ZNF154, ZNG582 and internal reference genes, fluorescent groups and quenching groups were attached to the 5' and 3' ends of the probes, and then the required primers and probes were synthesized by a nucleic acid sequence synthesis company.

[0105] 2. Sample collection, nucleic acid extraction and important sulfate conversion;

[0106] For patients with oral cancer, mouthwash or cotton swab specimens are collected; for patients with esophageal cancer, the exfoliated cell specimens are collected by the net method. It is recommended to extract DNA using a nucleic acid extraction kit and perform bisulfite conversion on the DNA to obtain B-DNA.

[0107] 3. preparing the reaction system;

[0108] The PCR reaction system should include buffer, dNTP, magnesium ions, primer pairs and probes for gene methylation detection, DNA polymerase, and nucleic acid converted from sample DNA.

[0109] 4. PCR amplification;

[0110] Set the program parameters on the fluorescent quantitative PCR instrument and perform automated testing.

[0111] 5. Interpretation of results;

[0112] According to the clinical interpretation criteria for gene methylation, single genes are first interpreted as negative or positive and assigned values ​​of 0 and 1, or given weighted scores. Then the results of the combined detection of multi-gene methylation are calculated and interpreted according to the interpretation criteria.

[0113] Experimental Example 1:

[0114] Mouthwash or lesion swab samples were collected from 115 patients with oral cancer and 84 patients with benign lesions with known pathological diagnosis results; among them, there were 159 males and 40 females with an average age of 53 years old; among the oral cancer patients, there were 3 cases of palate cancer, 4 cases of jaw cancer, 34 cases of cheek cancer, 5 cases of floor of mouth cancer, 51 cases of tongue cancer, 4 cases of gingival cancer, and 14 cases of oropharyngeal cancer.

[0115] For details, see Figures 1 to 4 As shown in Table 1, when the methylation of any one of the NID2 gene, PAX1 gene, ZNF154 gene, and ZNG582 gene is used as a primer probe composition for oral cancer detection, the positive rate of the target gene methylation in different pathological diagnosis results is shown in Table 1, and the critical value, sensitivity and specificity of the target gene methylation in diagnosing oral cancer are shown in Table 2.

[0116] Table 1 The positive rate of single gene methylation in different pathological diagnosis results

[0117]

[0118] Table 2 Critical value, sensitivity and specificity of single gene methylation for diagnosing oral cancer

[0119]

[0120] Furthermore, in addition to the above, any two gene methylation combinations of the NID2 gene, PAX1 gene, ZNF154 gene, and ZNG582 gene can be used as primer probe combinations for oral cancer detection. In this case, the sensitivity and specificity of any two gene methylation combinations of the NID2 gene, PAX1 gene, ZNF154 gene, and ZNG582 gene in diagnosing oral cancer are shown in Table 3.

[0121] Table 3 Sensitivity and specificity of dual gene methylation in diagnosing oral cancer

[0122]

[0123] Furthermore, in addition to the above, any three gene methylation combinations of NID2 gene, PAX1 gene, ZNF154 gene, and ZNG582 gene can be used as primer probe combinations for oral cancer detection. In this case, the sensitivity and specificity of any three gene methylation combinations of NID2 gene, PAX1 gene, ZNF154 gene, and ZNG582 gene in diagnosing oral cancer are shown in Table 4.

[0124] Table 4 Sensitivity and specificity of three-gene methylation in diagnosing oral cancer

[0125]

[0126] Furthermore, in addition to the above, the methylation combination of the four genes NID2 gene, PAX1 gene, ZNF154 gene, and ZNG582 gene can also be used as a primer probe combination for oral cancer detection. At this time, the sensitivity and specificity of the methylation combination of the four genes NID2 gene, PAX1 gene, ZNF154 gene, and ZNG582 gene in diagnosing oral cancer are shown in Table 5.

[0127] Table 5 Sensitivity and specificity of four-gene methylation in diagnosing oral cancer

[0128]

[0129] Experimental Example 2:

[0130] A total of 414 patients with clear pathological diagnosis of esophageal sites were collected, including 290 males and 124 females, of whom 86 had esophageal cancer and 328 had benign esophageal lesions. 84 had esophageal squamous cell carcinoma and 2 had esophageal adenocarcinoma. Among the 328 benign lesions, 230 had esophagitis, 22 had Barrett's esophagus, 27 had esophageal squamous papilloma, 4 had esophageal squamous epithelial atypical hyperplasia, 32 had esophageal squamous epithelial hyperplasia, and 13 had other benign esophageal lesions.

[0131] For details, see Figures 5 to 8As shown, when the methylation of any one of the NID2 gene, PAX1 gene, ZNF154 gene, and ZNG582 gene is used as a primer probe composition for esophageal cancer detection, the critical value, sensitivity, and specificity of the target gene methylation in diagnosing esophageal cancer are shown in Table 6.

[0132] Table 6 Critical value, sensitivity and specificity of single gene methylation for diagnosis of esophageal cancer

[0133]

[0134] Furthermore, in addition to the above, the methylation of any two genes among the NID2 gene, PAX1 gene, ZNF154 gene, and ZNG582 gene can also be used as a primer probe combination for esophageal cancer detection. In this case, the sensitivity and specificity of the methylation combination of any two genes among the NID2 gene, PAX1 gene, ZNF154 gene, and ZNG582 gene in diagnosing esophageal cancer are shown in Table 7.

[0135] Table 7 Sensitivity and specificity of dual gene methylation in diagnosing esophageal cancer

[0136]

[0137] Furthermore, in addition to the above, the methylation of any three genes among the NID2 gene, PAX1 gene, ZNF154 gene, and ZNG582 gene can also be used as a primer probe combination for esophageal cancer detection. At this time, the sensitivity and specificity of the methylation combination of any three genes among the NID2 gene, PAX1 gene, ZNF154 gene, and ZNG582 gene in diagnosing esophageal cancer are shown in Table 8.

[0138] Table 8 Sensitivity and specificity of three-gene methylation in diagnosing esophageal cancer

[0139]

[0140] Furthermore, in addition to the above, the methylation combination of the four genes NID2 gene, PAX1 gene, ZNF154 gene, and ZNG582 gene can also be used as a primer probe combination for esophageal cancer detection. At this time, the sensitivity and specificity of the methylation combination of the four genes NID2 gene, PAX1 gene, ZNF154 gene, and ZNG582 gene in diagnosing esophageal cancer are shown in Table 9.

[0141] Table 9 Sensitivity and specificity of four-gene methylation in diagnosing esophageal cancer

[0142]

[0143] See also Fig. 9As shown, the weighted combination of methylation of the four genes: NID2m positive scored 5 points, PAX1m positive scored 3 points, ZNF154m positive scored 6 points, ZNF582m scored 4 points, and negative scored 0 points. The combined score of methylation of the four genes is the sum of the methylation scores of the four genes.

[0144] The above description is only a preferred embodiment of the present invention and is not intended to limit the present invention. For those skilled in the art, the present invention may have various modifications and variations. Any modification, equivalent replacement, improvement, etc. made within the spirit and principle of the present invention shall be included in the protection scope of the present invention.

Claims

1. A primer-probe composition for oral cancer and esophageal cancer detection, characterized in that: The primer probe composition includes a biomarker combination consisting of NID2 gene, PAX1 gene, ZNF154 gene and ZNF582 gene as a primer probe sequence corresponding to the methylation marker, and the primer probe sequence is specifically represented as follows: The forward primer sequence of NID2 gene: GGTTGAGTTTTCGTCGTCGTT, the rear primer sequence of NID2 gene: CTACTACTACTACCGTTACTAATATTACGA, the probe sequence of NID2 gene: CGCTACACCCAAACGAACTCTTCCCAC; The forward primer sequence of PAX1 gene: GATAGTTCGGAGTTTAAGGGTAAATCG, the rear primer sequence of PAX1 gene: AACTACAATACGCCGCGCTC, the probe sequence of PAX1 gene: CGACTCCTCTACGCCCTTACCCACTC; The forward primer sequence of ZNF154 gene: GTCGTATTTATTTGAGTTGGCGTTT, the rear primer sequence of ZNF154 gene: AAACCGCTATCCCCGAATCC, the probe sequence of ZNF154 gene: TACCAATATCGCCCGTCGCTCCCGA; The forward primer sequence of ZNF582 gene: CGCGTTTTCGGTAGTTTAGGG, the rear primer sequence of ZNF582 gene: TAACGCAACATCGATATACTTTATACG, the probe sequence of ZNF582 gene: ACGCCATCTTCCGACTACGCACGA.

2. The primer-probe combination according to claim 1, characterized in that It also includes a set of primer probe sequences corresponding to a reference marker GAPDH gene, which are specifically shown as follows: The forward primer sequence of GAPDH gene: GAGGTTAAATATAGTTGTTGA, The forward primer sequence of GAPDH gene: CCCAAAACTTTAATTTACCA, The probe sequence of GAPDH gene: ACCTATCCTTCCTAACTCT.

3. Use of a primer-probe combination as claimed in claim 2 in the preparation of a kit for detecting oral cancer and esophageal cancer.

4. The use according to claim 3, characterized in that: When the NID2 gene, PAX1 gene, ZNF154 gene and ZNF582 gene are used in combination as a detection primer probe composition, the judgment criteria are: GENE1m+GENE2m+GENE3m+GENE4>3, that is, NID2 gene, PAX1 gene, ZNF154 gene and ZNF582 gene are all positive and are judged as positive; GENE1m+GENE2m+GENE3m+GENE4>2 is positive, that is, any three genes among NID2 gene, PAX1 gene, ZNF154 gene and ZNF582 gene are positive; GENE1m+GENE2m+GENE3m+GENE4>1 is positive, that is, any two genes among NID2 gene, PAX1 gene, ZNF154 gene and ZNF582 gene are positive; GENE1m+GENE2m+GENE3m+GENE4>0 is positive, that is, any one of the NID2 gene, PAX1 gene, ZNF154 gene and ZNF582 gene is positive; Among them, GENE1m represents the first gene methylation detection result of the four gene methylation combination, GENE2m represents the second gene methylation detection result of the four gene methylation combination, GENE3m represents the third gene methylation detection result of the four gene methylation combination, and GENE4m represents the fourth gene methylation detection result of the four gene methylation combination.